Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults

Pharmacotherapy

Volumn 22, Issue 9 I, 2002, Pages 1140-1156

  MacLaren, Robert ^a   Jung, Rose ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METHYLPREDNISOLONE; PHOSPHOLIPASE A2; TRANSCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL INSUFFICIENCY; ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL TRIAL; CORTICOSTEROID THERAPY; HEMODYNAMICS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; LUNG INJURY; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SURVIVAL RATE; ACUTE DISEASE; ADRENAL CORTEX; ADULT; CRITICAL ILLNESS; LUNG DISEASE;

ACUTE DISEASE; ADRENAL CORTEX; ADRENAL CORTEX HORMONES; ADULT; CLINICAL TRIALS; CRITICAL ILLNESS; HUMANS; LUNG DISEASES; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS;

EID: 0036708215     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.13.1140.33519     Document Type: Review

References (130)

1. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
2. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
3. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study
4. Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987
5. Epidemiology of sepsis syndrome in 8 academic medical centers: Academic medical center consortium sepsis project working group
6. Epidemiology of sepsis: An update
7. The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination
8. The acute respiratory distress syndrome
9. The role of the host defence response in the progression and outcome of ARDS: Pathophysiological correlations and response to glucocorticoid treatment
10. Acute respiratory distress syndrome: Resource use and outcomes in 1985 and 1995, trends in mortality and comorbidities
11. Infections and the inflammatory response in acute respiratory distress syndrome
12. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome
13. Treating patients with severe sepsis
14. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock
15. Adrenocortical response and cortisone replacement in systemic inflammatory response syndrome
16. The continuing story of corticosteroids in the treatment of septic shock
17. Corticosteroids for septic shock
18. Corticosteroid therapy in severe illness
19. Corticosteroids and the vascular tone: Mapping the messenger maze
20. Endothelial and vascular smooth muscle function in sepsis
21. Role of cytokines in the neuroendocrine-immune system axis
22. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
23. Neuroendocrine-immune interactions
24. Endocrine-paracrine interaction in communication between the immune and endocrine systems: Activation of the hypothalamic pituitary-adrenal axis in inflammation
25. Cytokines and the hypothalamicpituitary-adrenal axis
26. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions
27. Nuclear factor κ B: A pivotal role in the systemic inflammatory response syndrome and new target for therapy
28. Role of NF-κB in the mortality of sepsis
29. Immunosuppression by glucocorticosteroids: Inhibition of NF-κB activity through induction of IκB synthesis
30. Characterization of mechanisms involved in transrepression of NF-κ B by activated glucocorticoid receptors
31. Physical association and functional antagonism between the p65 subunit of the transcription factor NF-κB and the glucocorticoid receptor
32. Cross-talk between nuclear factor κ-B and the steroid hormone receptors: Mechanisms of mutual antagonism
33. Immunoregulatory genes and immunosuppression by glucocorticoids
34. Role of transcriptional activation of I κ B α in mediation of immunosuppression by glucocorticoids
35. Glucocorticoid resistance in asthma
36. The glucocorticoid receptor gene
37. Cytokine serum levels during severe sepsis in human IL-6 as a marker of severity
38. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines
39. Serum cytokine levels in human septic shock: Relation to multiple-organ failure and mortality
40. Inflammatory response in patients with septic shock secondary to generalized peritonitis
41. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome
42. High IL-6 serum levels are associated with septic shock and mortality in septic shock patients with severe leukopenia due to hematological malignancies
43. Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock
44. Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis
45. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans
46. Patterns of cytokine evolution (tumor necrosis factor-α and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma
47. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis
48. Persistent elevation of inflammatory cytokines predicts poor outcome in ARDS: Plasma IL-1β and IL-6 are consistent and efficient markers of outcome over time
49. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome
50. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome
51. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: Prognostic indicators
52. Inflammatory mediators in the bronchoalveolar lavage fluid and plasma in leukopenic patients with septic shock-induced acute respiratory distress syndrome
53. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: Relation with subsequent adult respiratory distress syndrome and multiple organ failure
54. Procalcitonin and cytokine levels: Relationship to organ failure and mortality in pediatric septic shock
55. Cytokine balance in the lungs of patients with acute respiratory distress syndrome
56. The association between mortality rates and the decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with adult respiratory distress syndrome
57. Adrenal insufficiency in critically ill patients
58. Hormones in the critically ill patient: To intervene or not to intervene
59. Adrenocortical function: An indicator of severity of disease and survival in chronic critically ill patients
60. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: Possible role of endothelin and atrial natriuretic hormone
61. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: Altered response to corticotropin-releasing hormone
62. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
63. Adrenal insufficiency occurring during septic shock: Incidence, outcome, and relationship to peripheral cytokine levels
64. Adrenal function in patients with sepsis
65. Cortisol response to corticotropin and survival in septic shock
66. Spectrum of serum cortisol response to ACTH in ICU patients: Correlation with degree of illness and mortality
67. Endocrine profiles for outcome prediction from the intensive care unit
68. Adrenocortical dysfunction in acute medical illness
69. Variations in adrenocortical responsiveness during severe bacterial infections: Unrecognized adrenocortical insufficiency in severe bacterial infections
70. Plasma cortisol levels in patients with septic shock
71. Adrenocortical function during septic shock
72. Serum cortisol levels in severely stressed patients
73. Cortisol replacement in severely stressed patients
74. A comparison of the adrenocortical response during septic shock and after complete recovery
75. Concordance of endogenous cortisol and phospholipase A2 levels in gramnegative septic shock: A prospective study
76. Prediction of outcome in intensive care patients using endocrine parameters
77. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock
78. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome
79. Duration of glucocorticoid treatment and outcome in sepsis: Is the right drug used the wrong way?
80. Tumor necrosis factor α inhibits the hormonal response to the pituitary gland to hypothalamic releasing factors
81. The hypothalamic-pituitary-adrenal axis in critical illness: Response to dexamethasone and corticotropin-releasing hormone
82. Potential functions of plasma steroid-binding proteins
83. Patterns of corticosteroidbinding globulin and free cortisol index during septic shock and multitrauma
84. Decreased immunoreactivity and binding activity of corticosteroid-binding globulin in serum in septic shock
85. Serum depletion of corticosteroid binding activities: An early marker of human septic shock
86. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of dominant negative β isoform: A mechanism for the generation of glucocorticoid resistance
87. Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-γ
88. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids
89. Suprarenal cortisol hormone and salt in the treatment of pneumonia and other severe infections
90. Steroid controversy in sepsis and septic shock: A meta-analysis
91. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature
92. Steroids in the treatment of clinical septic shock
93. The effects of high-dose corticosteroids in patients with septic shock: A prospective, controlled study
94. Hypothermia in the sepsis syndrome and clinical outcome: The methylprednisolone severe sepsis study group
95. The cardiopulmonary response to massive doses of steroids in patients with septic shock
96. Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine responses
97. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome
98. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve
99. Corticosteroid effect on early β-adrenergic down-regulation during circulatory circulator), shock: Hemodynamic study and β-adrenergic receptor assay
100. Effect of hydrocortisone on phenylephrine: Mean arterial pressure dose-response relationship in septic shock
101. Effect of corticosteroids on nuclear factor κB activation and hemodynamics in late septic shock
102. Adrenal failure in the critically ill
103. Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoids
104. Relative adrenal insufficiency in patients with septic shock
105. Contribution of cortisol deficiency to septic shock
106. Beneficial effects of corticosteroids in septic shock
107. Adrenal failure in the critically ill
108. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock
109. The effectiveness of hydrocortisone in the management of severe infections
110. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
111. Hydrocortisone reverses refractory septic shock
112. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone
113. Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock
114. Reversal of late septic shock with supraphysiologic doses of hydrocortisone
115. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors
116. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment
117. Chronic adult respiratory distress syndrome: A role for corticosteroids?
118. Established adult respiratory distress syndrome successfully treated with corticosteroids
119. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome
120. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome?
121. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: Patterns of response and predictors of outcome
122. Late steroid therapy in primary acute lung injury
123. Established acute respiratory distress syndrome: Benefit of corticosteroid rescue therapy
124. Corticosteroids in life-threatening varicella pneumonia
125. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome
126. Glucocorticoid therapy alters hormonal and cvtokine responses to endotoxin in man
127. Role of glucocorticoid hormones in arginine vasopressin gene regulation
128. Efficacy and safety of recombinant human activated protein C for severe sepsis